Evogene Ltd. (EVGN.TA)
Tel Aviv · ILA · Healthcare · Biotechnology
ILA 116.50 (+2.92%) as of
Key statistics
- Market cap
- 15.83M
- Forward P/E
- -0.30
- EPS (TTM)
- -4.94
- Dividend yield
- 0.00%
- 52-week range
- 110.00 – 427.90
- Beta
- 0.72
- Revenue (TTM)
- 1.66M
- Profit margin
- 0.00%
- Volume
- 73.99k
About Evogene Ltd.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Rehovot, Israel
- Employees
- 38
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.